High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study
The Pharmacogenomics Journal2011Vol. 12(6), pp. 499–506
Citations Over TimeTop 10% of 2011 papers
Getnet Yimer, Wondwossen Amogne, Abiy Habtewold, Eyasu Makonnen, N. Ueda, Akira Suda, Alemayehu Worku, Walter E. Haefeli, Jürgen Burhenne, Getachew Aderaye, Lars Lindquist, Eleni Aklillu
Related Papers
- → Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients(2001)832 cited
- → Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results(2005)108 cited
- → Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz(2016)13 cited
- → Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing(2019)10 cited
- → Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients(2023)